Triple agonist targeting GLP-1, GIP, and glucagon — the most potent metabolic peptide class.
Simultaneously activates three receptors: GLP-1 (appetite/insulin), GIP (insulin/fat metabolism), and glucagon (energy expenditure/fat oxidation). The glucagon component increases metabolic rate, adding a third mechanism for weight loss.
Phase 3 trials ongoing as of 2026. TRIUMPH-4 trial showed ~24% average body weight loss — the highest recorded for any peptide in this class. Not yet FDA approved.
The triple receptor agonism is a significant advancement over dual agonists. The glucagon receptor activation increases resting energy expenditure, providing a metabolic boost on top of reduced calorie intake.